Skip to content

A study to determine the role of genetic differences and environmental exposures as risk factors for dementias and parkinsonism in Nigeria

Nationwide study of environmental risk factors and candidate gene-environment interactions in neurodegenerative disorders in Nigeria

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN10548575
Enrollment
3000
Registered
2023-03-07
Start date
2020-05-01
Completion date
Unknown
Last updated
2023-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative diseases (Alzheimer's disease and related dementias (ADRD)

Interventions

Study participants (persons with ADRD and PDAP) will be recruited from participating hospitals across the six geopolitical zones of Nigeria under the guidance of study neurologists. All dementia cases

Sponsors

Tertiary Education Trust Fund (TETFUND)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. ADRD or PDAP diagnosed based on standardized clinical research criteria (with or without corroborating additional diagnostic information) 2. Neurologically healthy volunteers

Exclusion criteria

Exclusion criteria: 1. Non-consent 2. Unable to complete clinical assessments due to disability

Design outcomes

Primary

MeasureTime frame
The association between each specified environmental risk factor documented in the Environmental Risk Questionnaire (ERQ) (residential history, smoking and tobacco, alcohol use, diet, occupation, toxicants, pesticides, caffeine, head injury, NSAID and calcium channel blocker use) and genetic polymorphisms in SNCA REP1 and APOE and ADRD and PDAP will be measured by comparing the presence of the risk factor compared in cases (dementia i.e. ADRD, and parkinsonism i.e. PDAP) and controls. Specifically, the study will report on: 1. Relative risk associated with specified environmental exposures in dementia versus healthy controls 2. Relative risk associated with specified environmental exposures in parkinsonism versus healthy controls 3. Hazard ratios comparing the frequency of APOE polymorphisms in cases (dementia and parkinsonism) and controls 4. Hazard ratios comparing the frequency of SNCA REP1 polymorphisms in cases (dementia and parkinsonisms) and controls. 1. Environmental risk exposure measured using Environmental Risk Questionnaire at baseline (enrolment) 2. Genetic variability in APOE and SNCA REP1 measured using genotyping for polymorphic variability/allele frequencies at baseline (enrolment)

Secondary

MeasureTime frame
Combined effects (gene-environment interactions) will be analysed by comparing the combined effects of all environmental risk factors and the genetic polymorphisms (measured at baseline [enrolment]) on the risk of dementia and parkinsonism. Computational analysis will be employed as the statistical method for data analysis. The outcomes will be reported as risk ratios.

Countries

Nigeria

Contacts

Public ContactMoyinoluwa Olajide
olajide.moyinoluwa@gmail.com+234 (0)8110612416

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 6, 2026